سعر انابرامين 50مجم 30 قرص 2022

Clomipramine 50 mg film-coated tablets made by Sigma Pharmaceutical Industries, Egypt, a tricyclic antidepressant; 30 tablets.

• Major depressionPopulation: AdultsPharmaco (Australia) Ltd - TGA Product Information
• Obsessive-compulsive disorders and phobias in adultsPopulation: AdultsPharmaco (Australia) Ltd - TGA Product Information
• Cataplexy associated with narcolepsyPopulation: AdultsPharmaco (Australia) Ltd - TGA Product Information

• Very common adverse effects include dry mouth, constipation, nausea, drowsiness, dizziness, tremor and weight gain; common effects include orthostatic hypotension, sinus tachycardia and palpitations; blood dyscrasias (e.g. agranulocytosis) are very rare.General active-ingredient information · Pharmaco (Australia) Ltd - TGA Product Information

• Known hypersensitivity to clomipramine or excipients; cross-sensitivity to tricyclic antidepressants of the dibenzazepine group.General active-ingredient information · Pharmaco (Australia) Ltd - TGA Product Information
• Concomitant use with an MAO inhibitor, or within 14 days before or after treatment with an irreversible MAOI (or within 14 days before moclobemide).General active-ingredient information · Pharmaco (Australia) Ltd - TGA Product Information
• Acute and recovery stages of myocardial infarction; congenital long QT syndrome.General active-ingredient information · Pharmaco (Australia) Ltd - TGA Product Information

• Boxed warning: antidepressants increased the risk of suicidal thinking and behavior in children, adolescents and young adults in short-term studies; monitor all patients for clinical worsening, suicidality and unusual changes in behavior.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Seizures were the most significant risk identified (cumulative incidence about 1.45% at 1 year at doses up to 300 mg/day); limit the daily dose to 250 mg in adults and 3 mg/kg (or 200 mg) in children and adolescents; use caution with a history of seizures or predisposing factors.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Clinical worsening and suicide risk: patients should be closely monitored for clinical worsening and suicidality, especially at the start of treatment and at dose changes.General active-ingredient information · Pharmaco (Australia) Ltd - TGA Product Information

• MAO inhibitors (including moclobemide)ContraindicatedContraindicated; allow at least 14 days between an MAOI and clomipramine (either direction) because of severe interactions such as hypertensive crisis, hyperpyrexia, convulsions and serotonin syndrome.Pharmaco (Australia) Ltd - TGA Product Information
• Serotonergic agents (SSRIs, SNRIs, tricyclic antidepressants, lithium)Serotonin syndrome can possibly occur on co-administration.Pharmaco (Australia) Ltd - TGA Product Information
• CYP2D6 inhibitorsMay increase concentrations of clomipramine and its active metabolite up to about 3-fold in extensive metabolisers.Pharmaco (Australia) Ltd - TGA Product Information

• Experience in pregnancy is limited; treatment should be avoided during pregnancy and only considered if the expected benefits justify the potential risk to the fetus.General active-ingredient information · Pharmaco (Australia) Ltd - TGA Product Information
• Safety in pregnancy has not been established; not recommended during pregnancy and in women of child-bearing potential not using contraception.General active-ingredient information · SAHPRA PI/PIL repository
• Clomipramine passes into breast milk; babies should be weaned or the medication gradually withdrawn.General active-ingredient information · Pharmaco (Australia) Ltd - TGA Product Information

English text not available for this section.